On April 12, Dr. Jeff Smaill and Dr. Adam Patterson spoke on “The Design, Discovery and Clinical Development of Tarloxotinibbromide: A Hypoxia-Activated Irreversible EGFR Inhibitor.”
Both are are researchers at the Cancer Society Research Center, University of Auckland, New Zealand. Smaill has been focusing on medicinal chemistry research for more than 20 years, while Patterson specializes in pharmacological research. They are dedicated to the design and synthesis of hypoxia-activated oncology pro-drugs targeting the hypoxic conditions found in many tumor cells. They have collaborated on evaluating preclinical data of many compounds and initiated clinical studies of PR610 and PR-104, which have promising research prospects.